Eli Lilly Aims To Expand Weight-Loss Drug Trials To Those At Risk, Not Just Overweight
Eli Lilly Aims To Expand Weight-Loss Drug Trials To Those At Risk, Not Just Overweight
Ricks also mentioned the potential for expanding the use of these drugs to individuals with a BMI below 25 who are classified as having a healthy weight but are at risk of conditions like diabetes or vascular dementia. He emphasized the need to consider different BMI cut-offs for certain ethnic groups, such as Pacific Islanders, who are known to contract type-two diabetes earlier and at a lower BMI.In a groundbreaking move, Eli Lilly (NYSE:LLY) is set to test its weight-loss medications on individuals who are not overweight but are at risk of gaining weight.
禮來公司（紐約證券交易所代碼：LLY）將對不超重但有體重增加風險的人群測試其減肥藥物，這是一項開創性的舉措。
What Happened: Dave Ricks, CEO of Eli Lilly, announced that the company is considering lowering the BMI threshold for its anti-obesity drugs, Mounjaro and Zepbound. Currently, the BMI cut-off for trials is 27 in the U.S. and northern Europe. Ricks suggested that a BMI of 25 might be more suitable, Financial Times reported on Monday.
發生了什麼：禮來公司首席執行官戴夫·裏克斯宣佈，該公司正在考慮降低其抗肥胖藥物Mounjaro和Zepbound的體重指數門檻。目前，在美國和北歐，試驗的體重指數截止值爲27。據《金融時報》週一報道，裏克斯表示，體重指數爲25可能更合適。
Ricks pointed out that trials for Zepbound and the experimental weight-loss pill orforglipron included patients with a BMI of 30 and above, or those with a BMI of 27 and above with weight-related health issues. He argued for lowering the threshold, especially for orforglipron, which results in more modest weight loss.
裏克斯指出，Zepbound和實驗性減肥藥或forglipron的試驗包括體重指數爲30及以上的患者，或體重指數爲27及以上的有體重相關健康問題的患者。他主張降低閾值，尤其是orforglipron的門檻，這樣可以更適度地減肥。
Ricks also mentioned the potential for expanding the use of these drugs to individuals with a BMI below 25 who are classified as having a healthy weight but are at risk of conditions like diabetes or vascular dementia. He emphasized the need to consider different BMI cut-offs for certain ethnic groups, such as Pacific Islanders, who are known to contract type-two diabetes earlier and at a lower BMI.
裏克斯還提到，有可能將這些藥物的使用範圍擴大到體重指數低於25的人，這些人被歸類爲體重健康，但有患糖尿病或血管性癡呆等疾病的風險。他強調需要爲某些族裔群體考慮不同的體重指數界限，例如太平洋島民，衆所周知，他們較早感染二型糖尿病，體重指數較低。
The demand for Zepbound and Novo Nordisk's Wegovy has led to shortages, prompting both companies to invest heavily in manufacturing capacity. Eli Lilly has discouraged the off-label use of Zepbound for cosmetic purposes, emphasizing the need to prioritize diabetic and obese patients.
對Zepbound和諾和諾德旗下的Wegovy的需求導致了短缺，促使兩家公司對製造能力進行大量投資。禮來不鼓勵將Zepbound用於美容目的的標籤外用途，強調需要優先考慮糖尿病和肥胖患者。
Why It Matters: The decision to lower the BMI threshold for weight-loss drug trials comes at a time when Eli Lilly is experiencing significant success in the weight-loss drug market. The company's stock has soared due to the success of its weight-loss medications. However, the company is also facing competition from knockoff drugs, which it claims could be unsafe.
爲何重要：降低減肥藥物試驗的體重指數閾值的決定是在禮來公司在減肥藥物市場取得巨大成功之際做出的。由於其減肥藥物的成功，該公司的股票飆升。但是，該公司也面臨着來自仿製藥的競爭，它聲稱仿冒藥可能不安全。
Additionally, Eli Lilly stock hit resistance after a significant rally. This indicates that while the company is performing well, it is also navigating market challenges and competition.
此外，禮來公司股票在大幅上漲後觸及阻力。這表明，儘管該公司表現良好，但它也在應對市場挑戰和競爭。
- Has Medical Marijuana Been Forgotten In Cannabis Reform? 'Its Therapeutic Benefits Are Critical'
- 大麻改革中醫用大麻被遺忘了嗎？「它的治療功效至關重要」
Photo via Shutterstock
照片來自 Shutterstock
This story was generated using Benzinga Neuro and edited by Pooja Rajkumari
這個故事是使用 Benzinga Neuro 創作的，由 Pooja Rajkumari
